Profile
Warren Thomas Brown served as a Non-Executive Director at Mesa Minerals Ltd.
in 2010, at CBio Ltd.
in 2011, and as an Independent Non-Executive Director at Invion Ltd.
from 2013 to 2018.
Former positions of Warren Thomas Brown
| Companies | Position | End |
|---|---|---|
| INVION LIMITED | Director/Board Member | 2018-03-21 |
CBio Ltd.
 CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | Director/Board Member | 2011-11-28 |
| MESA MINERALS LIMITED | Director/Board Member | 2010-06-21 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| INVION LIMITED | Health Technology |
| Private companies | 2 |
|---|---|
Mesa Minerals Ltd.
 Mesa Minerals Ltd. Other Metals/MineralsNon-Energy Minerals Mesa Minerals Ltd. engages in hydrometallurgical process technology. Its products includes electrolytic manganese dioxide, electrolytic manganese metal, micro nutrient, granulated manganese sulfate, and manganese ore. The company was founded on October 26, 1984 and is headquartered in Applecross, Australia. | Non-Energy Minerals |
CBio Ltd.
CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | Health Technology |
- Stock Market
- Insiders
- Warren Thomas Brown
